PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
Status:
Active, not recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Trial assessing atezolizumab (anti-PD-L1) as treatment option for patients with mycosis
fungoides/sezary syndrome having progressed under or after previous therapy
For this study, we invite patients suffering from mycosis fungoides and Sézary syndrome who
have progressed after initial therapy or have failed to respond to previous therapy.
Mycosis fungoides and Sézary syndrome are cancers in which lymphocytes* become malignant
(cancerous) and affect the skin. In mycosis fungoides, the disease is generally limited to
the skin, and people develop flat or raised areas on their skin where the lymphocytes have
accumulated. Sometimes even larger aggregations of lymphocytes occur in the skin or lymph
nodes, resulting in tumors. In Sézary syndrome, the skin is often reddened or itchy, and some
abnormal lymphocytes circulate in the blood.
* Lymphocytes are a type of immune cells that is made in the bone marrow and is found in the
blood. Lymphocytes have a number of roles in the immune system, including the production of
antibodies and other substances that fight infections and other diseases.
In standard practice, the disease will be treated with conventional chemotherapy that
unfortunately has a limited lasting benefit. In this study, we want to see if a new treatment
option can optimize and improve response and make benefit last as long as possible. This new
treatment option is immunotherapy, using atezolizumab (Tecentriq).
Immunotherapy is a cancer treatment that uses antibodies made in the laboratory from a single
type of immune system cell. These antibodies can identify substances on cancer cells or
normal cells that may help cancer cell grow. The antibodies attach to the substances and kill
the cancer cells, block their growth, or keep them from spreading. Atezolizumab blocks a
protein called PD-L1 (programmed death-ligand 1) from binding to its receptor found on the
surface of lymphocytes. It helps to restore the immune activity of the body against the
cancer.
Atezolizumab is already used to treat adults with a cancer that affects the bladder and the
urinary system, called urothelial carcinoma, and a cancer that affects the lungs, called
non-small cell lung cancer.
In this trial, patients will receive atezolizumab for one year unless the tumor starts
growing again or this is not considered suitable for them anymore or they wish to stop the
treatment.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC